Sign Out
Hypersensitivity to the active substance or to any of the excipients listed in Description.
Concomitant administration of strong CYP3A4 inducers or dabigatran (see Interactions).
Congenital long QT syndrome.
Familial history of sudden death or polymorphic ventricular arrhythmia.
QT/QTc interval >500 msec, regardless of the correction method (see Dosage & Administration and Precautions).
Continue with Google